GI CANCERS

Olaparib and pembrolizumab appear to be a safe and tolerable combination therapy for patients with advanced cholangiocarcinoma.

According to new KEYNOTE-590 study findings, pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer showed clinical benefit.

In subjects with recurrent hepatocellular carcinoma who underwent liver transplant, both progression-free survival and overall survival were prolonged with manageable adverse events.

In the CheckMate 649 trial, durable survival benefit was achieved with Nivolumab plus chemotherapy in patients with gastric or gastroesophageal junction cancer.

Sintilimab treatment in pancreatic cancer shows mixed efficacy results in the phase 3 CISPD3 trial.

In the phase 3 KEYNOTE-394 trial, pembrolizumab and best supportive care prolongs survival in patients.

In a phase 3 study, patients with biliary tract cancer who received adjuvant oral fluoropyrimidine derivative S-1 lived longer than patients who underwent surgery.

According to updated findings from a cohort of the KRYSTAL-1 trial adagrasib may be active in previously treated KRAS G12C¬–mutant gastrointestinal tumors.

With an orphan drug designation in tow, MT-601 will soon be investigated in combination with chemotherapy in phase 1 clinical trial.

Results from the phase 3 KEYNOTE-062 study appear mixed for both pembrolizumab monotherapy versus chemotherapy and pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Single nucleotide polymorphisms such as NOTCH1, SEMA4D, NLRC5, and IL6R, may be predictive of nivolumab toxicity in advanced gastric cancer.

Results presented during the 2022 Gastrointestinal Cancers Symposium showed that 58.6% of evaluable patients experienced complete regression and fibrosis with no tumor cells.

Updated survival results from the phase 2 DESTINY-Gastric01 trial reveal the survival benefit of trastuzumab deruxtecan HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

An overall survival improvement for the combination of durvalumab and tremelimumab has been reported by the HIMALAYA clinical trial lead investigator.

TOPAZ-1 results reveal promise for durvalumab administered in combination with gemcitabine and cisplatin to patients with advanced biliary tract cancer.

A study of cinrebafusp alfa is underway to evaluate its safety and efficacy in combination with other therapies in patients with gastric or gastroesophageal junction cancers.

A fast track designation has been granted to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

The phase 2/3 GRANITE-CRC-1L clinical trial has been initiated.

Katherine Poruk, MD, discusses upcoming surgical advances being made the field of pancreatic cancer.

Andreana Holowatyj, PhD, MSCI, discusses the characteristics of appendiceal cancer and what differentiates it from colorectal cancer.

A phase 2 study of surufatinib in patients with biliary tract carcinoma showed some benefit and a larger phase 3 study is underway.

Andrea Holowatyj, PhD, MSCI delved into the growing issue of early-onset appendiceal cancer, how it impacts certain groups, and what efforts can improve outcomes for these patients in the future.

Chukwuemeka Ihemelandu, MD, explains the role of surgery in prolonging life and disease progression in patients with upper gastrointestinal cancers.

Recent genomic profiling studies revealed that approximately 40% of patients with biliary tract cancers harbor actionable genomic mutations.

In an interview with Targeted Oncology, Susan Pandya, MD discussed the impact ivosidenib has had on the cholangiocarcinoma space, along with remaining unmet clinical needs.

Lynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.

In an interview with Targeted Oncology, Katherine Poruk, MD, surgical oncologist, Cancer Treatment Centers of America, discussed the pancreatic treatment paradigm with an emphasis on the role of surgery.

Expert oncologist Milind Javle, MD, reviews the diagnosis and treatment of intrahepatic cholangiocarcinoma in a 61-year-old who presents with jaundice and changes in stool and urine color.

The FDA has granted orphan drug designation to LYT-200 for the treatment of patients with pancreatic cancer. The drug is currently under investigation in phase 1/2 clinical trial for the treatment of pancreatic cancer and other metastatic solid tumors.

According to Andrew S. Barbas, MD, of Duke Health, the scarcity of testing that can provide accurate results in patients with pancreatic cancer contributes to diagnoses in the advanced stages of the disease and consequently to poor prognoses.